Monday, October 5, 2026

Enterprise AI Agents Are Being Bought Faster Than Companies Can Feed Them Data

Banks, insurers and software vendors are committing to AI agents, and every respondent in one survey plans to use them within two years. The same survey says access to company data is the weak point. That source failed our reliability check, so we flag it.

LM Salvado

September 29, 2026

Enterprise AI Agents Are Being Bought Faster Than Companies Can Feed Them Data
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The claim that frames everything, and why we hold it loosely

The most quotable statistic in this story is also the least certain. MIT Technology Review's piece on scaling agents with trustworthy data says that within two years, 100% of respondents plan to be using agentic AI, and 69% expect to use it widely.1 It also says that in organizations categorized as 'data laggards', AI access to company data falls to 30% or less.1 Our topic summary attributes a further figure to Google Cloud research: companies average AI access to only 45% of their data. The excerpt we hold does not show that number, so treat it as unconfirmed.

Our own measurement of this source is poor. Only 0% of 11 checked claims from it held up against their sources.1 That is a small sample, but it is a reason to read the headline numbers as directional, not settled. The story is that adoption plans are running ahead of data readiness. The exact gap is not established.

What is actually shipping: governance before capability

The concrete evidence in the past two months comes from vendors selling control over agents rather than raw model power. On July 21, 2026, Box announced agent guardrails, oversight of third-party agent activity, prompt injection detection and access policies based on agent classification.2 A customer, Tatsutoshi Murata of Nomura Research Institute, said: "As we rapidly advance our utilization of AI agents, we expect Box—which has consistently led the development of security management capabilities for secure collaboration—to provide the administrative features needed to safely leverage this new era of AI."2 Nomura also values Box's multi-vendor support, which lets it switch between AI models.2

A day later, Manulife and Microsoft announced a five-year agreement. Manulife will adopt Microsoft's Frontier Suite, deploy Microsoft Agent 365 and expand Microsoft 365 Copilot to more than 30,000 employees.3 Shamus Weiland said the partnership gives Manulife "the trusted foundation to advance AI across our global operations."3 The trust language in both announcements matters. Buyers are asking for the safeguards before they scale up.

Both announcements come from NewsEOD, a source where 57% of 4,953 checked claims held up.2,3 That is better than the survey source above, but it still means about four in ten claims did not hold. Press-release language such as 'confidence' and 'responsibly' is the vendor's own description.

The startups: selling labor, not software

The CB Insights interviews show a consistent pitch. Covecta's Ben Thomas describes deploying "seasoned banker agents" for workforce productivity, workflow automation and portfolio management, serving banks, non-bank lenders, building societies, credit unions and private credit firms in the US and UK.4 He also says that for these institutions, "we are not just disrupting their software budget but their labor budget as well."4

Penguin AI makes the same move in healthcare. Glenn Herzberg says the company defines its market as administrative labor spend rather than the healthcare IT software budget. He says US healthcare administration runs about a trillion dollars a year, about a quarter of total health spend, with published estimates putting around $570 billion of that in work that has no effect on health outcomes.5 That is a founder-side market-sizing claim, not an audited figure.

Maisa AI's David Villalon defines his market as process automation of core business and production tasks at regulated industries, work that must be auditable, reproducible and hallucination resistant.6 The requirement is the same one that data readiness raises. An agent that cannot reach or trust the underlying data cannot be audited.

Investor Emily Man of Primary describes the origin of Casap, another company in this wave. The founders had "experienced the pain points of disputes firsthand at their respective large fintech companies."7 On the funding side, Latitude, a payments platform built around stablecoin-to-local-currency transfers, raised a $35M Series A on September 10, 2026.8 Its pitch is payments infrastructure, not agents, so it is a weaker data point for this story than the others.

The compute layer: Nvidia's verified numbers

The dossier links Nvidia to much of the agent tooling. Nvidia develops NeMo Agent Toolkit, NeMo Guardrails and NeMo microservices, and Mistral AI is a customer.9 Mistral's founders include Timothée Lacroix.9 Our dossier holds no detail on the Microsoft-Mistral or Siemens-NVIDIA deals named in the topic, so we say nothing further about them.

What we can state plainly is checked against SEC filings. Nvidia's cost of revenue, the direct cost of what it sells, was $16.621 billion in fiscal 2024, $32.639 billion in fiscal 2025 and $62.475 billion in fiscal 2026.10 That is roughly 3.8 times the fiscal 2024 level in two years. Cost of revenue rises with sales, so it is a rough proxy for how much product is moving, not a measure of profit. Cash, by fiscal year, was $7.28 billion, $8.589 billion and $10.605 billion.11 The latest quarter in the series, Q1 2027, shows $13.237 billion, against $15.234 billion in Q1 2026.11 Nvidia's cash therefore does not rise in a straight line.

Earnings per share were $11.93 in fiscal 2024, $2.94 in fiscal 2025 and $4.90 in fiscal 2026.12 That series is not smooth, and the dossier does not explain why. Do not compare the first figure to the later ones without checking how each was reported. We do not know whether the periods are on the same share basis.

If you hold a broad index fund, you may hold Nvidia. The dossier does not give its weighting, so we will not guess at it.

What the evidence does and does not say

Our topic summary also mentions insider selling at C3.ai as a sign of mixed investor conviction. We hold no verified data on that, so we cannot assess it. It should not be read as a finding.

Via News's reading of the material is that the gap between plans and data readiness is the story, and the vendor announcements are early evidence that buyers know it. That is our interpretation, and it rests on a survey source that failed our reliability check. It would be stronger with a second, independent measurement of how much company data agents can actually reach.

What to watch

  • Whether a better-sourced study confirms the 30% figure for data laggards and the 45% average, since our current source does not.
  • Whether Box, Manulife and Microsoft report results from their agent deployments, not just announcements.
  • Whether Nvidia's cash and cost of revenue continue to climb in the coming filings.
  • Whether the labor-budget pitch from Covecta and Penguin AI shows up as named customers and revenue, not market-size claims.

Sources:
1 MIT Technology Review, "Scaling AI agents with trustworthy data" (undated) — source reliability: 0% of 11 checked claims held up
2 NewsEOD, "Box Unveils New Controls to Secure AI Agents Operating Across Enterprise Content" (2026-07-21) — source reliability: 57% of 4953 checked claims held up
3 NewsEOD, "Manulife Expands Partnership with Microsoft to Accelerate Enterprise AI Governance and Innovation" (2026-07-22) — source reliability: 57% of 4953 checked claims held up
4 CB Insights, "Executive Interview: Covecta" (undated)
5 CB Insights, "Executive Interview: Penguin AI" (undated)
6 CB Insights, "CEO Interview: David Villalon, Maisa" (undated)
7 CB Insights, "Investor Interview: Primary on Casap" (undated)
8 Via News event record — Latitude raises $35M Series A (September 10, 2026)
9 Via News entity graph — Nvidia relationships (undated)
10 Via News verified data — Nvidia cost_of_revenue, SEC filing (FY 2024, FY 2025, FY 2026)
11 Via News verified data — Nvidia cash, SEC filing (FY 2024–FY 2026; Q1 2026 and Q1 2027)
12 Via News verified data — Nvidia eps, SEC filing (FY 2024, FY 2025, FY 2026)

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· July 21, 2026
    Box Unveils New Controls to Secure AI Agents Operating Across Enterprise Content
  2. [2]News articleCB Insights
    CEO Interview: David Villalon, Maisa
  3. [3]News articleCB Insights
    Executive Interview: Covecta
  4. [4]News articleCB Insights
    Executive Interview: Penguin AI
  5. [5]News articleCB Insights
    Investor Interview: Primary on Casap
  6. [6]News articleYahoo Finance· July 22, 2026
    Manulife Expands Partnership with Microsoft to Accelerate Enterprise AI Governance and Innovation
  7. [7]News articleMIT Technology Review
    Scaling AI agents with trustworthy data
  8. [8]News articleMotley Fool
    C3.ai CEO Thomas Siebel Sells 453,000 Shares for $4.8 Million
  9. [9]News articleCB Insights
    CEO Interview: Zorro
  10. [10]News articleIEEE Spectrum
    How Melbourne’s AI and Data Center Flywheel Is Accelerating Research Innovation
  11. [11]News articleYahoo Finance· July 21, 2026
    Microsoft and Mistral expand strategic partnership to give enterprises and regulated industries frontier AI they can control
  12. [12]News articleYahoo Finance· July 27, 2026
    Siemens advances self-verifying agentic AI workflows for semiconductor and PCB design
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com